�ݺ�ߣshows by User: pvoors

�ݺ�ߣshows by User: pvoors / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: pvoors / Tue, 11 Jun 2024 18:54:28 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: pvoors Cell Therapy Expansion and Challenges in Autoimmune Disease /slideshow/cell-therapy-expansion-and-challenges-in-autoimmune-disease/269629963 healthadvancescell-therapy-autoimmune-240611185428-625c4f4e
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point. ]]>
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point. ]]> Tue, 11 Jun 2024 18:54:28 GMT /slideshow/cell-therapy-expansion-and-challenges-in-autoimmune-disease/269629963 pvoors@slideshare.net(pvoors) Cell Therapy Expansion and Challenges in Autoimmune Disease pvoors There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescell-therapy-autoimmune-240611185428-625c4f4e-thumbnail.jpg?width=120&height=120&fit=bounds" /> There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities. In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions. Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved. Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.

Cell Therapy Expansion and Challenges in Autoimmune Disease from Health Advances

]]> 179 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescell-therapy-autoimmune-240611185428-625c4f4e-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Insights from Leading CNS Players: V2 /slideshow/insights-from-leading-cns-players-257545335/257545335 healthadvancescnsoverview-230424194117-eb96749f
This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.]]>
This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.]]> Mon, 24 Apr 2023 19:41:17 GMT /slideshow/insights-from-leading-cns-players-257545335/257545335 pvoors@slideshare.net(pvoors) Insights from Leading CNS Players: V2 pvoors This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescnsoverview-230424194117-eb96749f-thumbnail.jpg?width=120&height=120&fit=bounds" /> This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.

Insights from Leading CNS Players: V2 from Health Advances

]]> 109 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescnsoverview-230424194117-eb96749f-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 : Insights from Leading CNS Players /slideshow/insights-from-leading-cns-players-257540810/257540810 healthadvancescnsoverview-230424131051-dfa1385a
Insights from Leading CNS Players By Michael Davitian and David Dopfel, PhD This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: * Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments * Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) * Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. ### Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.]]>
Insights from Leading CNS Players By Michael Davitian and David Dopfel, PhD This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: * Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments * Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) * Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. ### Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.]]> Mon, 24 Apr 2023 13:10:51 GMT /slideshow/insights-from-leading-cns-players-257540810/257540810 pvoors@slideshare.net(pvoors) : Insights from Leading CNS Players pvoors Insights from Leading CNS Players By Michael Davitian and David Dopfel, PhD This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: * Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments * Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) * Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. ### Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescnsoverview-230424131051-dfa1385a-thumbnail.jpg?width=120&height=120&fit=bounds" /> Insights from Leading CNS Players By Michael Davitian and David Dopfel, PhD This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series: CNS Year in Review: Introduction and Large CNS Diseases https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/ CNS Year in Review: Going Digital https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/ CNS Year in Review: Novel Modalities https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/ Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities: * Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments * Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie) * Increasing interest in deal-making among larger players as a means of bolstering portfolios In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities. ### Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology. David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.

: Insights from Leading CNS Players from Health Advances

]]> 90 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescnsoverview-230424131051-dfa1385a-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Health Advances Demystifying COVID Testing - 4th Edition.pdf /slideshow/health-advances-demystifying-covid-testing-4th-editionpdf-252168617/252168617 healthadvancesdemystifyingcovidtesting-4thedition-220712185152-60dc328b
• As we enter the endemic phase of COVID-19, we wanted to share our final edition of Demystifying COVID-19 Testing. In this edition, we provide an update on testing dynamics and share our assessment of the impact on the industry and our predictions for the future.]]>
• As we enter the endemic phase of COVID-19, we wanted to share our final edition of Demystifying COVID-19 Testing. In this edition, we provide an update on testing dynamics and share our assessment of the impact on the industry and our predictions for the future.]]> Tue, 12 Jul 2022 18:51:52 GMT /slideshow/health-advances-demystifying-covid-testing-4th-editionpdf-252168617/252168617 pvoors@slideshare.net(pvoors) Health Advances Demystifying COVID Testing - 4th Edition.pdf pvoors • As we enter the endemic phase of COVID-19, we wanted to share our final edition of Demystifying COVID-19 Testing. In this edition, we provide an update on testing dynamics and share our assessment of the impact on the industry and our predictions for the future. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancesdemystifyingcovidtesting-4thedition-220712185152-60dc328b-thumbnail.jpg?width=120&height=120&fit=bounds" /> • As we enter the endemic phase of COVID-19, we wanted to share our final edition of Demystifying COVID-19 Testing. In this edition, we provide an update on testing dynamics and share our assessment of the impact on the industry and our predictions for the future.

Health Advances Demystifying COVID Testing - 4th Edition.pdf from Health Advances

]]> 463 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancesdemystifyingcovidtesting-4thedition-220712185152-60dc328b-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Health advances ai in diagnostic development /slideshow/health-advances-ai-in-diagnostic-development-241663545/241663545 healthadvances-aiindiagnosticdevelopment-210121195136
Health advances ai in diagnostic development]]>
Health advances ai in diagnostic development]]> Thu, 21 Jan 2021 19:51:36 GMT /slideshow/health-advances-ai-in-diagnostic-development-241663545/241663545 pvoors@slideshare.net(pvoors) Health advances ai in diagnostic development pvoors Health advances ai in diagnostic development <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvances-aiindiagnosticdevelopment-210121195136-thumbnail.jpg?width=120&height=120&fit=bounds" /> Health advances ai in diagnostic development

Health advances ai in diagnostic development from Health Advances

]]> 117 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvances-aiindiagnosticdevelopment-210121195136-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Health advances covid-19_3 /slideshow/health-advances-covid193/236963032 healthadvancescovid-193-200716121057
• Much is still unknown regarding the markers of disease and recovery process for SARS-CoV-2, including if and what immunity arises and which tests or markers can be useful in assessing immunity status • A multi-phased plan is required to reopen the economy post-COVID-19, with significantly daily testing capacity (millions) required at all stages o Challenges with scientific validation, regulatory, manufacturing, and ongoing logistics must be overcome to successfully ramp up testing capacities in the US o Hundreds of molecular and serology tests are now available, but many have limited accuracy (high false positive/negative rates) due to the rapid development and lack of validation of these tests • In this edition of Demystifying COVID-19 Testing, we highlight what is required now and in the future to move to a “new normal” and why it is challenging to get this testing up and running at volumes needed in the US]]>
• Much is still unknown regarding the markers of disease and recovery process for SARS-CoV-2, including if and what immunity arises and which tests or markers can be useful in assessing immunity status • A multi-phased plan is required to reopen the economy post-COVID-19, with significantly daily testing capacity (millions) required at all stages o Challenges with scientific validation, regulatory, manufacturing, and ongoing logistics must be overcome to successfully ramp up testing capacities in the US o Hundreds of molecular and serology tests are now available, but many have limited accuracy (high false positive/negative rates) due to the rapid development and lack of validation of these tests • In this edition of Demystifying COVID-19 Testing, we highlight what is required now and in the future to move to a “new normal” and why it is challenging to get this testing up and running at volumes needed in the US]]> Thu, 16 Jul 2020 12:10:57 GMT /slideshow/health-advances-covid193/236963032 pvoors@slideshare.net(pvoors) Health advances covid-19_3 pvoors • Much is still unknown regarding the markers of disease and recovery process for SARS-CoV-2, including if and what immunity arises and which tests or markers can be useful in assessing immunity status • A multi-phased plan is required to reopen the economy post-COVID-19, with significantly daily testing capacity (millions) required at all stages o Challenges with scientific validation, regulatory, manufacturing, and ongoing logistics must be overcome to successfully ramp up testing capacities in the US o Hundreds of molecular and serology tests are now available, but many have limited accuracy (high false positive/negative rates) due to the rapid development and lack of validation of these tests • In this edition of Demystifying COVID-19 Testing, we highlight what is required now and in the future to move to a “new normal” and why it is challenging to get this testing up and running at volumes needed in the US <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescovid-193-200716121057-thumbnail.jpg?width=120&height=120&fit=bounds" /> • Much is still unknown regarding the markers of disease and recovery process for SARS-CoV-2, including if and what immunity arises and which tests or markers can be useful in assessing immunity status • A multi-phased plan is required to reopen the economy post-COVID-19, with significantly daily testing capacity (millions) required at all stages o Challenges with scientific validation, regulatory, manufacturing, and ongoing logistics must be overcome to successfully ramp up testing capacities in the US o Hundreds of molecular and serology tests are now available, but many have limited accuracy (high false positive/negative rates) due to the rapid development and lack of validation of these tests • In this edition of Demystifying COVID-19 Testing, we highlight what is required now and in the future to move to a “new normal” and why it is challenging to get this testing up and running at volumes needed in the US

Health advances covid-19_3 from Health Advances

]]> 669 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescovid-193-200716121057-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition /pvoors/ha101-demystifying-sarscov2-testing-for-covid19second-edition healthadvancescovid-192-200508125434
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition]]>
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition]]> Fri, 08 May 2020 12:54:34 GMT /pvoors/ha101-demystifying-sarscov2-testing-for-covid19second-edition pvoors@slideshare.net(pvoors) HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition pvoors HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescovid-192-200508125434-thumbnail.jpg?width=120&height=120&fit=bounds" /> HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition

HA101: Demystifying SARS-CoV-2 Testing for COVID-19-Second Edition from Health Advances

]]> 542 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescovid-192-200508125434-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition /slideshow/ha101-demystifying-sarscov2-testing-for-covid19first-edition/233422697 healthadvancescovid-191-200508124903
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition]]>
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition]]> Fri, 08 May 2020 12:49:03 GMT /slideshow/ha101-demystifying-sarscov2-testing-for-covid19first-edition/233422697 pvoors@slideshare.net(pvoors) HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition pvoors HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescovid-191-200508124903-thumbnail.jpg?width=120&height=120&fit=bounds" /> HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition

HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition from Health Advances

]]> 365 0 https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescovid-191-200508124903-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Biopharma Sales Resilience through Economic Recession /slideshow/biopharma-sales-resilience-through-economic-recession/233005728 health-advances-biopharma-recession-200501150210
Analysis of 2008/9’s Great Recession on the Sales of Established, Branded Drug Classes.]]>
Analysis of 2008/9’s Great Recession on the Sales of Established, Branded Drug Classes.]]> Fri, 01 May 2020 15:02:10 GMT /slideshow/biopharma-sales-resilience-through-economic-recession/233005728 pvoors@slideshare.net(pvoors) Biopharma Sales Resilience through Economic Recession pvoors Analysis of 2008/9’s Great Recession on the Sales of Established, Branded Drug Classes. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/health-advances-biopharma-recession-200501150210-thumbnail.jpg?width=120&height=120&fit=bounds" /> Analysis of 2008/9’s Great Recession on the Sales of Established, Branded Drug Classes.

Biopharma Sales Resilience through Economic Recession from Health Advances

]]> 740 0 https://cdn.slidesharecdn.com/ss_thumbnails/health-advances-biopharma-recession-200501150210-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-pvoors-48x48.jpg?cb=1718138037 Health Advances is a strategy consulting firm that helps clients realize growth opportunities worldwide for healthcare technologies, products and services. We work with senior executives and investors on their highest-stakes strategic decisions. We provide our clients fresh perspectives, actionable insights and innovative strategies to unlock their companies’ growth potential. healthadvances.com/ https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescell-therapy-autoimmune-240611185428-625c4f4e-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/cell-therapy-expansion-and-challenges-in-autoimmune-disease/269629963 Cell Therapy Expansion... https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescnsoverview-230424194117-eb96749f-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/insights-from-leading-cns-players-257545335/257545335 Insights from Leading ... https://cdn.slidesharecdn.com/ss_thumbnails/healthadvancescnsoverview-230424131051-dfa1385a-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/insights-from-leading-cns-players-257540810/257540810 : Insights from Leadin...